系统综述与荟萃分析:瘦型非酒精性脂肪性肝病患者组织学疾病严重程度的意义
该系统综述与荟萃分析纳入8项研究,比较瘦型(BMI≤25 kg/m²,n=493)与非瘦型(超重/肥胖,n=2209)非酒精性脂肪性肝病(NAFLD)患者的组织学结局。结果显示,超重/肥胖NAFLD患者的纤维化评分、NAFLD活动度评分和脂肪变评分均显著高于瘦型NAFLD患者;瘦型NAFLD患者发生非酒精性脂肪性肝炎(NASH)的风险显著低于超重/肥胖患者(OR 0.58,95%CI 0.34-0.97,P=0.04)。作者认为瘦型NAFLD患者组织学特征趋向较轻,但需后续纵向评估以理解其临床影响。
要点
- 超重/肥胖NAFLD患者纤维化评分显著高于瘦型NAFLD患者(均数差0.28±0.13,P=0.032)。
- 瘦型NAFLD患者NASH风险显著低于超重/肥胖患者(OR 0.58,95%CI 0.34-0.97,P=0.04)。
- 超重/肥胖NAFLD患者NAFLD活动度评分(均数差0.58±0.16,P=0.0004)和脂肪变评分(均数差0.23±0.07,P=0.002)均显著高于瘦型患者。
核心结论
- 瘦型NAFLD患者与超重/肥胖NAFLD患者相比,组织学特征趋向较轻。
- 需后续纵向评估以理解这些发现的临床影响;超重/肥胖患者平均纤维化评分约25%的 increment 提示肥胖可能预测更差的长期预后。
研究设计与样本
- 系统综述与荟萃分析,通过截至2017年7月的系统检索纳入8项比较瘦型(n=493)与超重/肥胖(n=2209)NAFLD患者组织学结局的研究。
主要发现
- 超重/肥胖NAFLD患者纤维化评分显著高于瘦型NAFLD患者(P=0.032),两组均数差为0.28±0.13。
- 瘦型NAFLD患者(n=322)发生NASH的风险显著低于超重/肥胖NAFLD患者(n=1357)(OR 0.58,95%CI 0.34-0.97,P=0.04)。
- 超重/肥胖NAFLD患者NAFLD活动度评分显著高于瘦型NAFLD患者(均数差±SE:0.58±0.16,P=0.0004)。
- 超重/肥胖NAFLD患者脂肪变评分显著高于瘦型NAFLD患者(均数差±SE:0.23±0.07,P=0.002)。
关键数值与推荐
- 瘦型定义为BMI≤25 kg/m²。
- 纤维化评分量表范围为0-4分。
局限性
- 需后续纵向评估以理解这些发现的临床影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Current evidence suggests that lean and obese patients with nonalcoholic fatty liver disease (NAFLD) share an altered metabolic and cardiovascular profile. However, there is an incomplete understanding of the natural history of "lean-NAFLD." Indeed, an unanswered question is whether lean (BMI ≤ 25 Kg/m2 ) NAFLD-patients are protected from severe histological outcomes. AIM: To perform a meta-analysis with the goal of providing a quantitative estimation of the magnitude of fibrosis, as well as histological features associated with the disease severity, in lean versus overweight/obese-NAFLD patients. METHODS: Through a systematic search up to July 2017, we identified eight studies that compared histological outcomes in lean (n = 493) versus overweight/obese (n = 2209) patients. RESULTS: Relative to lean-NAFLD, overweight/obese-NAFLD patients showed significantly (P = .032) higher fibrosis scores; the observed difference in means between the two groups, which is the absolute difference between the mean value of fibrosis score [0-4] ± standard error, was 0.28 ± 0.13. The risk of having nonalcoholic steatohepatitis-NASH (OR 0.58 95% CI 0.34-0.97) was significantly lower in lean-NAFLD (n = 322) than in overweight/obese-NAFLD (n = 1357), P = .04. Relative to lean-NAFLD, overweight/obese-NAFLD patients also have significantly greater NAFLD activity (difference in means ± SE: 0.58 ± 0.16, P = .0004) and steatosis (difference in means ± SE: 0.23 ± 0.07, P = .002) scores. CONCLUSIONS: Lean-NAFLD patients tend to show less severe histological features as compared to overweight/obese-NAFLD patients. Subsequent longitudinal assessment is needed to understand the clinical impact of these findings; however, the significant ~ 25% increment of mean fibrosis score in overweight/obese patients suggests that obesity could predict a worse long-term prognosis.
引用
- Sookoian S, Pirola CJ. Systematic review with meta-analysis: the significance of histological disease severity in lean patients with nonalcoholic fatty liver disease. Aliment Pharmacol Ther. 2017. PMID: 29083036. doi:10.1111/apt.14401
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。